ACER Annual CFF
$20.04 M
+$12.90 M+180.73%
31 December 2022
Summary:
As of February 5, 2025, ACER annual cash flow from financing activities is $20.04 million, with the most recent change of +$12.90 million (+180.73%) on December 31, 2022. During the last 3 years, it has risen by +$19.95 million (+21613.43%).ACER Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACER Quarterly CFF
$677.60 K
-$12.39 M-94.82%
30 June 2023
Summary:
As of February 5, 2025, ACER quarterly cash flow from financing activities is $677.60 thousand, with the most recent change of -$12.39 million (-94.82%) on June 30, 2023. Over the past year, it has dropped by -$2.85 million (-80.77%).ACER Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACER TTM CFF
$19.13 M
-$2.85 M-12.95%
30 June 2023
Summary:
As of February 5, 2025, ACER TTM cash flow from financing activities is $19.13 million, with the most recent change of -$2.85 million (-12.95%) on June 30, 2023. Over the past year, it has increased by +$4.48 million (+30.56%).ACER TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACER Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +180.7% | -80.8% | +30.6% |
| 3 y3 years | +10000.0% | -72.9% | +664.3% |
| 5 y5 years | -25.6% | +100.0% | +10000.0% |
ACER Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -53.1% | -98.4% | -64.7% |
Acer Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | $677.60 K(-94.8%) | $19.13 M(-12.9%) |
| Mar 2023 | - | $13.07 M(+198.1%) | $21.98 M(+9.7%) |
| Dec 2022 | $20.04 M(+180.7%) | $4.38 M(+338.2%) | $20.04 M(+28.0%) |
| Sept 2022 | - | $1.00 M(-71.6%) | $15.66 M(+6.8%) |
| June 2022 | - | $3.52 M(-68.3%) | $14.66 M(+31.7%) |
| Mar 2022 | - | $11.13 M(>+9900.0%) | $11.13 M(+55.9%) |
| Dec 2021 | $7.14 M(-33.4%) | $0.00(0.0%) | $7.14 M(-32.9%) |
| Sept 2021 | - | $0.00(0.0%) | $10.63 M(-30.8%) |
| June 2021 | - | $0.00(-100.0%) | $15.36 M(-14.0%) |
| Mar 2021 | - | $7.14 M(+104.4%) | $17.86 M(+66.6%) |
| Dec 2020 | $10.72 M(>+9900.0%) | $3.49 M(-26.1%) | $10.72 M(+48.3%) |
| Sept 2020 | - | $4.73 M(+88.8%) | $7.23 M(+188.8%) |
| June 2020 | - | $2.50 M(>+9900.0%) | $2.50 M(+2612.5%) |
| Mar 2020 | - | $0.00(0.0%) | $92.30 K(0.0%) |
| Dec 2019 | $92.30 K(-99.8%) | $0.00(0.0%) | $92.30 K(-48.6%) |
| Sept 2019 | - | $0.00(-100.0%) | $179.40 K(-99.6%) |
| June 2019 | - | $92.30 K(+6.0%) | $42.84 M(+0.3%) |
| Dec 2018 | $42.71 M(+58.5%) | $87.10 K(-99.8%) | $42.71 M(-21.1%) |
| Sept 2018 | - | $42.66 M(>+9900.0%) | $54.13 M(+103.4%) |
| June 2018 | - | $0.00(-100.0%) | $26.62 M(+0.2%) |
| Mar 2018 | - | -$38.70 K(-100.3%) | $26.55 M(-1.4%) |
| Dec 2017 | $26.94 M(>+9900.0%) | $11.51 M(-24.0%) | $26.94 M(+75.0%) |
| Sept 2017 | - | $15.15 M(<-9900.0%) | $15.39 M(+2916.5%) |
| June 2017 | - | -$65.30 K(-118.7%) | $510.20 K(+2.7%) |
| Mar 2017 | - | $348.90 K(-942.8%) | $497.00 K(+659.9%) |
| Dec 2016 | $65.40 K(-99.5%) | -$41.40 K(-115.4%) | $65.40 K(-89.1%) |
| Sept 2016 | - | $268.00 K(-441.4%) | $600.30 K(-28.1%) |
| June 2016 | - | -$78.50 K(-5.1%) | $835.00 K(-93.6%) |
| Mar 2016 | - | -$82.70 K(-116.8%) | $13.12 M(+0.2%) |
| Dec 2015 | $13.10 M(+1920.3%) | $493.50 K(-1.8%) | $13.10 M(+3.9%) |
| Sept 2015 | - | $502.70 K(-95.9%) | $12.60 M(-1.1%) |
| June 2015 | - | $12.20 M(<-9900.0%) | $12.75 M(+2246.3%) |
| Mar 2015 | - | -$104.90 K(<-9900.0%) | $543.30 K(-16.2%) |
| Dec 2014 | $648.20 K(-97.7%) | $0.00(-100.0%) | $648.20 K(-91.7%) |
| Sept 2014 | - | $648.20 K(>+9900.0%) | $7.81 M(-68.6%) |
| June 2014 | - | $0.00(0.0%) | $24.91 M(+0.7%) |
| Mar 2014 | - | $0.00(-100.0%) | $24.73 M(-13.0%) |
| Dec 2013 | $28.44 M(+618.7%) | $7.17 M(-59.6%) | $28.44 M(+33.6%) |
| Sept 2013 | - | $17.74 M(<-9900.0%) | $21.28 M(+184.2%) |
| June 2013 | - | -$175.80 K(-104.7%) | $7.49 M(-2.3%) |
| Mar 2013 | - | $3.71 M(>+9900.0%) | $7.66 M(+93.7%) |
| Dec 2012 | $3.96 M(-53.9%) | $8800.00(-99.8%) | $3.96 M(+0.2%) |
| Sept 2012 | - | $3.95 M(>+9900.0%) | $3.95 M(>+9900.0%) |
| June 2012 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 2012 | - | $0.00(0.0%) | -$18.00 K(-100.2%) |
| Dec 2011 | $8.58 M | $0.00(0.0%) | $8.58 M(+0.2%) |
| Sept 2011 | - | $0.00(-100.0%) | $8.57 M(+0.0%) |
| June 2011 | - | -$18.00 K(-100.2%) | $8.56 M(-0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2011 | - | $8.60 M(<-9900.0%) | $8.60 M(>+9900.0%) |
| Dec 2010 | $42.30 K(-99.4%) | -$17.30 K(+8550.0%) | $42.30 K(-99.2%) |
| Sept 2010 | - | -$200.00(-101.0%) | $5.00 M(-14.6%) |
| June 2010 | - | $19.20 K(-52.7%) | $5.86 M(-16.4%) |
| Mar 2010 | - | $40.60 K(-99.2%) | $7.00 M(+0.8%) |
| Dec 2009 | $6.95 M(-24.5%) | $4.94 M(+477.5%) | $6.95 M(+248.7%) |
| Sept 2009 | - | $855.60 K(-26.6%) | $1.99 M(-50.2%) |
| June 2009 | - | $1.17 M(-7768.4%) | $4.00 M(+41.8%) |
| Mar 2009 | - | -$15.20 K(+9.4%) | $2.82 M(-69.3%) |
| Dec 2008 | $9.20 M(+8075.8%) | -$13.90 K(-100.5%) | $9.20 M(-0.0%) |
| Sept 2008 | - | $2.87 M(<-9900.0%) | $9.20 M(+45.5%) |
| June 2008 | - | -$14.20 K(-100.2%) | $6.32 M(-1.6%) |
| Mar 2008 | - | $6.36 M(<-9900.0%) | $6.42 M(+5608.4%) |
| Dec 2007 | $112.50 K(-99.5%) | -$13.70 K(+24.5%) | $112.50 K(-52.4%) |
| Sept 2007 | - | -$11.00 K(-112.5%) | $236.50 K(-0.3%) |
| June 2007 | - | $88.20 K(+80.0%) | $237.30 K(-98.9%) |
| Mar 2007 | - | $49.00 K(-55.6%) | $21.31 M(+0.2%) |
| Dec 2006 | $21.26 M(+159.8%) | $110.30 K(-1181.4%) | $21.26 M(+0.3%) |
| Sept 2006 | - | -$10.20 K(-100.0%) | $21.19 M(-3.1%) |
| June 2006 | - | $21.16 M(>+9900.0%) | $21.88 M(+306.2%) |
| Mar 2006 | - | $0.00(-100.0%) | $5.39 M(-34.2%) |
| Dec 2005 | $8.18 M(+141.7%) | $40.20 K(-94.0%) | $8.18 M(+0.5%) |
| Sept 2005 | - | $674.30 K(-85.6%) | $8.14 M(+9.0%) |
| June 2005 | - | $4.67 M(+67.0%) | $7.47 M(+167.0%) |
| Mar 2005 | - | $2.80 M(>+9900.0%) | $2.80 M(+3287.4%) |
| Dec 2004 | $3.39 M(+5862.5%) | - | - |
| Mar 2004 | - | $22.60 K(+186.1%) | $82.60 K(+37.9%) |
| Dec 2003 | - | $7900.00(-84.6%) | $59.90 K(+5.5%) |
| Sept 2003 | $56.80 K(+71.6%) | $51.20 K(+5588.9%) | $56.80 K(+122.7%) |
| June 2003 | - | $900.00(-1000.0%) | $25.50 K(-11.5%) |
| Mar 2003 | - | -$100.00(-102.1%) | $28.80 K(+80.0%) |
| Dec 2002 | - | $4800.00(-75.9%) | $16.00 K(-51.8%) |
| Sept 2002 | $33.10 K(-77.7%) | $19.90 K(+373.8%) | $33.20 K(-77.5%) |
| June 2002 | - | $4200.00(-132.6%) | $147.80 K(-6.2%) |
| Mar 2002 | - | -$12.90 K(-158.6%) | $157.50 K(+2.1%) |
| Dec 2001 | - | $22.00 K(-83.6%) | $154.30 K(+4.1%) |
| Sept 2001 | $148.20 K(-75.6%) | $134.50 K(+867.6%) | $148.20 K(-60.6%) |
| June 2001 | - | $13.90 K(-186.3%) | $376.00 K(-5.8%) |
| Mar 2001 | - | -$16.10 K(-201.3%) | $399.00 K(-25.4%) |
| Dec 2000 | - | $15.90 K(-95.6%) | $535.10 K(-11.8%) |
| Sept 2000 | $606.80 K(-549.5%) | $362.30 K(+881.8%) | $606.70 K(+124.1%) |
| June 2000 | - | $36.90 K(-69.3%) | $270.70 K(+152.3%) |
| Mar 2000 | - | $120.00 K(+37.1%) | $107.30 K(+30.2%) |
| Dec 1999 | - | $87.50 K(+232.7%) | $82.40 K(-161.1%) |
| Sept 1999 | -$135.00 K | $26.30 K(-120.8%) | -$134.90 K(-16.3%) |
| June 1999 | - | -$126.50 K(-233.0%) | -$161.20 K(+364.6%) |
| Mar 1999 | - | $95.10 K(-173.3%) | -$34.70 K(-73.3%) |
| Dec 1998 | - | -$129.80 K | -$129.80 K |
FAQ
- What is Acer Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Acer Therapeutics?
- What is Acer Therapeutics annual CFF year-on-year change?
- What is Acer Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Acer Therapeutics?
- What is Acer Therapeutics quarterly CFF year-on-year change?
- What is Acer Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Acer Therapeutics?
- What is Acer Therapeutics TTM CFF year-on-year change?
What is Acer Therapeutics annual cash flow from financing activities?
The current annual CFF of ACER is $20.04 M
What is the all time high annual CFF for Acer Therapeutics?
Acer Therapeutics all-time high annual cash flow from financing activities is $42.71 M
What is Acer Therapeutics annual CFF year-on-year change?
Over the past year, ACER annual cash flow from financing activities has changed by +$12.90 M (+180.73%)
What is Acer Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ACER is $677.60 K
What is the all time high quarterly CFF for Acer Therapeutics?
Acer Therapeutics all-time high quarterly cash flow from financing activities is $42.66 M
What is Acer Therapeutics quarterly CFF year-on-year change?
Over the past year, ACER quarterly cash flow from financing activities has changed by -$2.85 M (-80.77%)
What is Acer Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ACER is $19.13 M
What is the all time high TTM CFF for Acer Therapeutics?
Acer Therapeutics all-time high TTM cash flow from financing activities is $54.13 M
What is Acer Therapeutics TTM CFF year-on-year change?
Over the past year, ACER TTM cash flow from financing activities has changed by +$4.48 M (+30.56%)